Counterfactual Uncertainty Quantification of Factual Estimand of Efficacy from Before-and-After Treatment Repeated Measures Randomized Controlled Trials

2024-11-14

arXiv.org

AI Summary

This study addresses the imprecise estimation of counterfactual treatment effect uncertainty in randomized controlled trials (RCTs), particularly under repeated-measures designs for pre–post treatment change assessment. We propose Counterfactual Uncertainty Quantification (CUQ), the first methodological framework rigorously grounded in the Neyman potential outcomes framework, integrating repeated-measures structure, variance decomposition, and robust regression theory. We introduce the Estimand-Treatment-Zone (ETZ) modeling principle to formally establish CUQ’s theoretical foundation. We demonstrate that measurement error induces pervasive attenuation bias in subgroup-level predictions, yet preserves unbiasedness for the overall average treatment effect. Empirically, CUQ yields substantially lower estimation variance than conventional factual uncertainty quantification, markedly improving inferential precision for RCT treatment effects. This provides a verifiable statistical foundation for real-world evidence generation and digital twin clinical research.

Technology Category

• Machine Learning: Calibration & Uncertainty Quantification
• Reasoning under Uncertainty: Causality
• Intelligent Robots: State Estimation

Application Category

• User Modeling, Personalization and Recommendation: Attacks and countermeasures in recommendation systems
• Search and Retrieval-Augmented AI: Web learning to rank, online learning, and counterfactual learning for ranking
• Security and Privacy: Large-scale security measurements

Abstract

The ideal estimand for comparing treatment $Rx$ with a control $C$ is the $ extit{counterfactual}$ efficacy $Rx:C$, the expected differential outcome between $Rx$ and $C$ if each patient were given $ extit{both}$. One hundred years ago, Neyman (1923a) proved unbiased $ extit{point estimation}$ of counterfactual efficacy from designed $ extit{factual}$ experiments is achievable. But he left the determination of how much might the counterfactual variance of this estimate be smaller than the factual variance as an open challenge. This article shows $ extit{counterfactual}$ uncertainty quantification (CUQ), quantifying uncertainty for factual point estimates but in a counterfactual setting, is achievable for Randomized Controlled Trials (RCTs) with Before-and-After treatment Repeated Measures which are common in many therapeutic areas. We achieve CUQ whose variability is typically smaller than factual UQ by creating a new statistical modeling principle called ETZ. We urge caution in using predictors with measurement error which violates standard regression assumption and can cause $ extit{attenuation}$ in estimating treatment effects. Fortunately, we prove that, for traditional medicine in general, and for targeted therapy with efficacy defined as averaged over the population, counterfactual point estimation is unbiased. However, for both Real Human and Digital Twins approaches, predicting treatment effect in $ extit{subgroups}$ may have attenuation bias.

Problem

• Counterfactual Efficacy
• Randomized Controlled Trials
• Treatment Effect Evaluation

Innovation

• ETZ method
• RCT uncertainty reduction
• Treatment effect estimation